Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

MEDA Says FDA Approved Dymista - Quick Facts

MEDA AB (MDABF.PK) said the U.S. Food and Drug Administration has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis, or SAR. In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment.

Anders Lönner, CEO of Meda AB, said, "...The approval of Dymista represents an important achievement for Meda's clinical development groups in the US and Europe. Meda's franchise in the allergy area is strengthened and gives opportunities for the company to grow and establish collaborations in the field. Dymista will be available in the US during the second half of 2012".

Click here to receive FREE breaking news email alerts for Meda AB and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
At least 15 people, including women and children, were killed in an overnight Israeli attack on a UN school housing refugees in Gaza, reports say. The UN Relief and Works Agency (UNRWA) confirmed it, and put the blame on Israel. The children were sleeping next to their parents on the floor of a classroom in a UN designated shelter in Gaza, when Israeli artillery hit them, UNRWA said in a stateme After turning lower over the course of the previous session, stocks are likely to move back to the upside in early trading on Wednesday. The major index futures are currently pointing to a higher open for the markets, with the Dow futures up by 59 points. Eurozone banks eased the credit standards for lending to businesses for the first time since the second quarter of 2007, the European Central Bank said in a report on Wednesday, helping to support economic recovery. "Credit standards for all loan categories eased in net terms in the second quarter...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.